Survodutide

About this material

Survodutide is supplied by Rierink Compounds as a laboratory research material. Made in Europe. It is a glucagon and GLP-1 receptor agonist peptide, listed separately from mazdutide. It sits with the peptides studied in laboratory research on incretin and metabolic signaling. The material is a lyophilized powder and is supplied unreconstituted. The companion reagent listed for it is BAC water. Store at −20 °C, dry and protected from light. For laboratory research use only. Not a medicine. Not for human or veterinary use. Rierink does not publish reconstitution volumes, dosing, or administration guidance.

Recommended reagent

This is the laboratory reagent listed with this lyophilized material.

Certificates

These certificates come from our supplier and relate to the supplier's batches. They are not Rierink's own independent tests of the exact vial you receive. Every Rierink vial carries our own internal lot number, and independent testing of our own lots is underway; results will be published per lot. We welcome independent testing: any customer or lab is free to test our products, and we're happy to share results sent to us.

Survodutide · 5 mg

Supplier certificate pending

Survodutide · 10 mg

Compound

Survodutide

Amount

10 mg

Purity

99.81%

Measured content

11.36 mg

PDF

Supplier-issued; cannot be independently verified.

Research briefings

• Survodutide Dual Agonist: Preclinical and Clinical EvidenceThe open-catalog entry for survodutide describes a synthetic acylated 29-amino-acid peptide dual agonist of glucagon and GLP-1 receptors supplied as high-purity lyophilized powder for laboratory metabolic research. Randomised trials report
• Favorable and unfavorable findings on TirzepatideClinical trials and meta-analyses of tirzepatide report substantial mean weight loss (15–21%), glycemic improvements, cardiometabolic benefits, heart failure event reduction, and superior weight loss versus semaglutide. These are accompanie
• Favorable and unfavorable findings on RetatrutideClinical trials of retatrutide (LY3437943), a GIP/GLP-1/glucagon triple receptor agonist, report substantial mean weight loss (18-25% at 80 weeks in phase 3 TRIUMPH studies), glycemic improvements, cardiometabolic benefits, and gains in knee osteoarthritis pain and obstructive sleep apnea. However, dose-dependent gastrointestinal adverse events, dysesthesia, increased heart rate, and higher discontinuation rates are consistently reported alongside inconclusive cardiovascular outcomes and data gaps on long-term safety.